Icahns

Rafael Henrique | Lightrocket | Getty ImagesIllumina on Thursday urged shareholders to reject Carl Icahn's three board nominees at this year's annual meeting, saying they would "threaten the progress" of the biotech company's core business.…

Carl IcahnAdam Jeffery | CNBC Biotech company Illumina pushed back Monday against Carl Icahn's proxy fight over the company's acquisition of cancer test developer Grail, saying the activist investor's board nominees "do not add value." The…